Form 4: Core Scientific Exec Sells Shares Under 10b5-1 Plan

Core Scientific, Inc. executive Todd DuChene reported the sale of common stock under a pre-arranged trading plan, with transactions occurring on June 29 and June 30, 2026.

Summary

• Todd DuChene, Chief Legal and Administrative Officer of Core Scientific, Inc., reported transactions involving the sale of common stock.
• These sales were executed under a Rule 10b5-1 trading plan adopted on December 5, 2025.
• On June 29, 2026, 8,800 shares were sold at a weighted average price of $25.99, 1,100 shares at a weighted average price of $27.42, and 100 shares at $27.95.
• On June 30, 2026, an additional 5,469 shares were sold at a price of $25.59.
• Following these transactions, DuChene beneficially owns 2,033,426 shares of common stock.
• The filing also notes shares withheld to cover tax obligations upon the vesting of restricted stock units.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative filing due to the insider selling, even though it was conducted under a pre-arranged plan. The reduction in executive ownership can be a signal of reduced confidence or a need for liquidity.

Positives

• The transactions were conducted under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider trading related sales.
• The company's stock is trading at prices between $25.56 and $27.95, suggesting a valuation that DuChene is willing to realize some gains from.

Negatives

• An executive is selling a significant number of shares (15,469 shares in total reported), which could be perceived negatively by the market.
• The sales represent a reduction in direct beneficial ownership by a key executive.

Risks

• The sales, even if under a 10b5-1 plan, could be interpreted by the market as a lack of confidence in future stock performance.
• The weighted average pricing indicates a range of sale prices, and the undertaking to provide specific price details suggests a need for transparency around the exact execution prices.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The Rule 10b5-1 plan implies a pre-determined strategy for future sales, but the specific outcomes are not detailed.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.56 to $26.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.86 to $27.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event for executives looking to diversify holdings or manage personal financial needs. The context of Core Scientific's business (likely related to digital assets or technology infrastructure given the ticker CORZ) would influence how such sales are perceived relative to industry-wide insider trading patterns.

Stakeholder Impact

• Shareholders: May view the executive's sales as a negative signal, potentially impacting short-term stock price sentiment.
• Employees: May interpret the sales in the context of company performance and executive confidence.
• Management: The sales are part of a pre-defined strategy, indicating adherence to established governance practices for insider trading.

Next Steps

• The Rule 10b5-1 plan may continue to execute further sales as per its terms.
• The company may need to address any market perception arising from the executive's stock sales.

Key Dates

Recommendation

The filing reports routine insider sales under a 10b5-1 plan, which are generally not indicative of a fundamental change in the company's prospects. While insider selling can create short-term negative sentiment, the pre-planned nature of these transactions suggests they are not necessarily a reflection of new negative information. Therefore, a 'hold' recommendation is appropriate, pending further company-specific developments or financial performance updates.

Keywords

Core Scientific, CORZ, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Todd DuChene, Beneficial Ownership, Securities Exchange Act